Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.600
+0.090 (5.96%)
At close: Aug 13, 2025, 4:00 PM
1.600
0.00 (0.00%)
After-hours: Aug 13, 2025, 6:30 PM EDT
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 37 employees as of December 31, 2024. The number of employees decreased by 12 or -24.49% compared to the previous year.
Employees
37
Change (1Y)
-12
Growth (1Y)
-24.49%
Revenue / Employee
n/a
Profits / Employee
-$1,109,081
Market Cap
49.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATNM News
- 13 days ago - Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit - PRNewsWire
- 7 weeks ago - Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting - PRNewsWire
- 2 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM - PRNewsWire
- 3 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM - GlobeNewsWire
- 3 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewsWire
- 3 months ago - Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - PRNewsWire
- 3 months ago - Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation - PRNewsWire
- 3 months ago - Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - PRNewsWire